Precision medicine with car cells in acute myeloid leukemia: where are we?

Area of Science:

• Immunology
• Oncology
• Genetics

Background:

• Chimeric antigen receptor (CAR) therapies represent a promising approach for treating acute myeloid leukemia (AML).
• The effectiveness of CAR-T and CAR-NK cells is significantly influenced by genetic mutations within the patient's leukemia cells.
• These mutations affect CAR cell function, including proliferation, persistence, resistance, and safety.

Purpose of the Study:

• To review how specific genetic mutations in AML modulate the efficacy of CAR-based immunotherapies.
• To identify vulnerabilities and resistance mechanisms associated with these mutations.
• To highlight the importance of personalized approaches in CAR therapy for AML.

Main Methods:

• Review of current literature on genetic mutations in AML and their impact on CAR therapies.
• Analysis of how mutations in key genes (e.g., FLT3, DNMT3A, NPM1, TP53, TET2, RUNX1, KMT2A) affect CAR cell function.
• Examination of resistance and vulnerability mechanisms in the context of AML genetics.

Main Results:

• Mutations in DNMT3A and NPM1 can enhance antigen expression, potentially improving CAR targeting in AML.
• Mutations in TP53 are associated with immune escape and resistance to CAR therapy.
• Specific genetic profiles dictate differential responses to CAR-based treatments.

Conclusions:

• Understanding mutation-specific effects is crucial for tailoring CAR therapies to individual AML patients.
• Genomic profiling and personalized engineering can optimize CAR therapy efficacy and minimize toxicity.
• Future strategies should integrate multiomic data to develop mutation-adapted CAR approaches for personalized AML immunotherapy.